Valeant Pharmaceuticals International, Inc. Form 4 March 19, 2014

March 19, 20	014										
FORM	4		~~~~~			~~~ .			OMB AF	PROVAL	
	UNITED	STATES		RITIES A shington,			NGE C	OMMISSION	OMB Number:	3235-0287	
Check th if no long	oer.								Expires:	January 31 2005	
subject to Section 1 Form 4 c	F CHANGES IN BENEFICIAL OWN SECURITIES					ERSHIP OF	Estimated a burden hour response	verage			
Form 5 obligatio may com <i>See</i> Instr 1(b).	ns Section 17(	(a) of the l	Public U		ding Cor	npan	y Act of	Act of 1934, 1935 or Section )			
(Print or Type l	Responses)										
			2. Issuer Name <b>and</b> Ticker or Trading Symbol				0	5. Relationship of Reporting Person(s) to Issuer			
			Valeant Pharmaceuticals International, Inc. [VRX]					(Check all applicable)			
(Last)	(Month/I			of Earliest Transaction /Day/Year)				Director 10% Owner X Officer (give title Other (specify below) below)			
2150 ST. El	LZEAR BLVD. V	WEST	03/17/2	014				· · · · · · · · · · · · · · · · · · ·	Couns. & Corp.	Secy.	
	(Street)			ndment, Da hth/Day/Year	-	ıl		6. Individual or Joi Applicable Line) _X_ Form filed by O	-	-	
LAVAL, A	8 H7L 4A8							Form filed by Me Person			
(City)	(State)	(Zip)	Tabl	e I - Non-I	Derivative	Secur	rities Acqu	iired, Disposed of,	or Beneficiall	y Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	3. Transactic Code (Instr. 8)	(Instr. 3,	(A) or	d of (D) 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common				Code V	Amount	(D)	Price	(, ,			
Stock, no par value	03/17/2014			М	5,000 (1)	А	\$ 6.45	28,999	D		
Common Stock, no par value	03/17/2014			S	5,000 (1)	D	\$ 141.72 (2)	23,999	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

## Edgar Filing: Valeant Pharmaceuticals International, Inc. - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number on f Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	f Derivative Expiration Date ecurities (Month/Day/Year) cquired A) or isposed of D) nstr. 3, 4,		7. Title and Ame Underlying Secu (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Ai or Ni of Sł
Non-Qualified Stock	\$ 6.45	03/17/2014		М	5,000 (1)	08/09/2008 <u>(3)</u>	08/09/2014	Common Shares, no par value	5

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships						
FB	Director	10% Owner	Officer	Other			
Chai-Onn Robert Roswell			EVP, Gen.				
2150 ST. ELZEAR BLVD. WEST			Couns. &				
LAVAL, A8 H7L 4A8			Corp. Secy.				
Signatures							

## by: Nicholas Zanoni for Robert Chai-Onn

03/19/2014

\*\*Signature of Reporting Person

Date

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) This number represents options exercised and sold pursuant to a 10b5-1 trading plan.

This number represents the weighted average sale price for all sales of common stock sold by the reporting officer pursuant to a 10b5-1 trading plan. Actual sale executions were in the range of \$141.63 and \$141.80. Upon request by the Securities and Exchange

(2) Hading plan. Actual safe executions were in the range of \$141.05 and \$141.05 optimized by the securities and Exchange
 (2) Commission, the issuer, or any security holder of the issuer, the reporting person will provide full information regarding the number of shares sold at each price.

The options vested one-fourth per year over four years starting from the date of grant with the first vest date falling on the first

(3) anniversary of the grant, the second vest date falling on the second anniversary of the grant, the third vest date falling on the third anniversary of the grant, and the fourth vest date falling fourth anniversary of the grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.